Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 8.86M | $214.0M | 10.40% | +2.14M | 2026-06-30 |
| NEA Management Company, LLC | 7.69M | $186.0M | 9.03% | -- | 2026-06-30 |
| BlackRock, Inc. | 6.84M | $165.0M | 8.03% | +1.21M | 2026-06-30 |
| TCG Crossover Management, LLC | 4.62M | $111.0M | 5.42% | -- | 2026-06-30 |
| Vestal Point Capital, LP | 4.60M | $111.0M | 5.40% | +996.5K | 2026-06-30 |
| Bvf Inc | 4.46M | $107.0M | 5.23% | -- | 2026-06-30 |
| Baker Bros. Advisors LP | 4.35M | $105.0M | 5.10% | -- | 2026-06-30 |
| State Street Corp | 3.73M | $90.0M | 4.38% | +377.4K | 2026-06-30 |
| Montanova Capital, LLC | 3.55M | $85.0M | 4.16% | -677.3K | 2026-06-30 |
| Vanguard Capital Management LLC | 3.41M | $82.0M | 4.00% | +312.7K | 2026-06-30 |
